BBVA USA Bancshares’s Novavax NVAX Stock Holding History

BBVA USA Bancshares’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,013	Closed	-$418K	–	514
2020 Q2	$418K	Buy	+5,013	New	+$192K	0.03%	385

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBVA USA Bancshares's NVAX Position: Q3 2020 in Review

BBVA USA Bancshares sold out of Novavax (NVAX) in Q3 2020, closing a stake of 5,013 shares — an estimated $418K sold.

BBVA USA Bancshares first reported a position in NVAX in Q2 2020 and held it in 1 quarter. The position peaked at $418K in Q2 2020. 311 funds tracked by Wall St. Rank hold NVAX as of Q3 2020.

BBVA USA Bancshares reported no remaining Novavax position as of Q3 2020 after selling out during the quarter.
BBVA USA Bancshares sold 5,013 Novavax shares in Q3 2020, an estimated $418K.
BBVA USA Bancshares first reported a position in Novavax in Q2 2020 and held it in 1 quarter.
BBVA USA Bancshares's Novavax position peaked at $418K in Q2 2020.
311 funds tracked by Wall St. Rank held Novavax as of Q3 2020.

Based on BBVA USA Bancshares's 13F filing for Q3 2020, filed 27 Oct 2020.